EUDAW EUDA Health Holdings Ltd
Price Chart
Executive Summary
EUDA Health announced the launch of a new skincare product, the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, under its exclusive global distributorship agreement with Chemokine Pte Ltd. The product is a beauty mask entering a large and growing market, but the filing provides no financial terms, revenue projections, or sales targets, making the material impact unquantifiable.
Actionable Insight
This is a routine product line extension with no disclosed financial terms. Monitor future quarterly filings for any revenue contribution from the Helixé line. Without sales data or guidance, this filing alone does not warrant a position change.
Key Facts
- EUDA launched the Regenixé Mask, an iPSC-derived skin stem cell secretome mask, under the Helixé product line.
- EUDA holds exclusive global distributorship rights for Helixé products from Chemokine Pte Ltd.
- The global face mask market is estimated at ~$7.95 billion in 2026, forecast to reach ~$9.08 billion by 2031 per Mordor Intelligence.
- No financial terms, revenue guidance, or sales targets were disclosed in the filing.
- The filing is a routine 6-K with a press release — no material financial data or binding commitments were provided.
Financial Impact
No financial figures disclosed — product launch with no revenue or cost guidance.
Risk Factors
- No disclosed financial terms or minimum purchase commitments from Chemokine or any distributor.
- The skincare market is highly competitive; EUDA's ability to generate meaningful revenue from this product is unproven.
- Forward-looking statements about market growth are not guarantees of EUDA's sales performance.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-026539 |
| Exhibit: ex99-1.htm | 0001493152-26-026539 |
| Document: 0001493152-26-026539-index-headers.html | 0001493152-26-026539 |
| Document: 0001493152-26-026539-index.html | 0001493152-26-026539 |
| Document: 0001493152-26-026539.txt | 0001493152-26-026539 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
2d ago
|
6-K
| $0.0258 awaiting T+5 | awaiting T+5 | — | $0.0460 (+78.29%) |
|
Jun 1, 2026
11d ago
|
6-K
| $0.0460 $0.0460 | · 0.00% | ▲ +2.75% | $0.0460 (+0.00%) |
|
Jun 1, 2026
11d ago
|
6-K
| $0.0460 $0.0460 | · 0.00% | ▲ +2.75% | $0.0460 (+0.00%) |
|
Apr 28, 2026
6w ago
|
6-K
| $0.0460 $0.0460 | · 0.00% | ▼ −3.11% | $0.0460 (+0.00%) |
|
Apr 27, 2026
6w ago
|
6-K
| $0.0460 $0.0460 | · 0.00% | ▲ +0.40% | $0.0460 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access